Barr Pharmaceuticals, Inc. (NYSE: BRL) confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE